MEK inhibitor monotherapy, while insufficient at preventing growth in most tumors, shows promising results in low-grade pediatric glioma with the KIAA1549–BRAF fusion or NF1 loss-of-function [66,67]. This evidence concerns the gene MAP2K7 and central nervous system cancer.